A Meta Model for a Blockchain-based Supply Chain Traceability

International audienceIn recent years, traceability has gained interest since some health issues like the mad cow scandal. Able to ensure a follow-up of products through each stage of their life-cycle, traceability provides consumers more visibility and guarantees on the items they buy. However, accessible information about items origins or content does not meet consumers, associations and regulatory services growing expectations. Furthermore, other concerns like counterfeiting as well as bad headline pressures in case of a product recall, urge firms to develop their trace- ability systems which currently show fragilities. Indeed, today, companies manage traceability in their way which creates silos. Consequently, information flow is slowed and limited along the chain. Based on these, the study discusses the concept of ag- gregating different companies traceability management systems into a single one covering all the supply chain. The concept implementation is made possible through collaborative platforms like the Blockchain. In terms of traceability, this technology presents interests in recording transactions in a transparent, reliable and secure ways. However, it first requires data to be structured before makes it concrete. The contribution of this paper is to provide a meta model as a first groundwork for a possible Blockchain implementation for supply chain traceability purposes. Its objective is to i) identify and monitor key traceabili- ty information regarded as master, event or transactional data ii) highlight the connections with actors and the sequence of events generated along the product journey. The meta model’s behaviour is then, illustrated through a case study from the pharmaceutical industry

Phostine 3.1a as a pharmacological compound with antiangiogenic properties against diseases with excess vascularization

Angiogenesis is a complex process leading to the growth of new blood vessels from existing vasculature, triggered by local proangiogenic factors such as VEGF. An excess of angiogenesis is a recurrent feature of various pathologic conditions such as tumor growth. Phostines are a family of synthetic glycomimetic compounds that exhibit anticancer properties, and the lead compound 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl2-oxo-2λ5-[1,2]oxaphosphinane (PST 3.1a) shows antiglioblastoma properties both in vitro and in vivo. In the present study, we assessed the effect of PST 3.1a on angiogenesis and endothelial metabolism. In vitro, PST 3.1a (10 µM) inhibited all steps that regulate angiogenesis, including migration, proliferation, adhesion, and tube formation. In vivo, PST 3.1a reduced intersegmental vessel formation and vascularization of the subintestinal plexus in zebrafish embryos and also altered pathologic angiogenesis and glioblastoma progression in vivo. Mechanistically, PST 3.1a altered interaction of VEGF receptor 2 and glycosylation-regulating protein galectin-1, a key component regulating angiogenesis associated with tumor resistance. Thus, these data show that use of PST 3.1a is an innovative approach to target angiogenesis.-Bousseau, S., Marchand, M., Soleti, R., Vergori, L., Hilairet, G., Recoquillon, S., Le Mao, M., Gueguen, N., Khiati, S., Clarion, L., Bakalara, N., Martinez, M. C., Germain, S., Lenaers, G., Andriantsitohaina, R. Phostine 3.1a as a pharmacological compound with antiangiogenic properties against diseases with excess vascularization